ASSOCIATION BETWEEN HLA MATCHING STATUS AND KIDNEY ALLOGRAFT FUNCTION: 3-MONTH SURVIVAL ANALYSIS IN LIVING DONOR TRANSPLANTATION

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/a60a3ef81d2f1a4fb2d71186dacc6e85.pdf

Abstract Title *

ASSOCIATION BETWEEN HLA MATCHING STATUS AND KIDNEY ALLOGRAFT FUNCTION: 3-MONTH SURVIVAL ANALYSIS IN LIVING DONOR TRANSPLANTATION

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Iri Kuswadi irikuswadi@yahoo.com Faculty of Medicine, Public Health and Nursing Gadjah Mada University Nephrology and Hypertension Division Yogyakarta Indonesia -

Co-author 2

Heru Prasanto heruprasanto@yahoo.com Faculty of Medicine, Public Health and Nursing Gadjah Mada University Nephrology and Hypertension Division Yogyakarta Indonesia -

Co-author 3

Metalia Puspitasari puspitasarimetalia@gmail.com Faculty of Medicine, Public Health and Nursing Gadjah Mada University Nephrology and Hypertension Division Yogyakarta Indonesia -

Co-author 4

Yulia Wardhani yulia.wardhani@gmail.com Faculty of Medicine, Public Health and Nursing Gadjah Mada University Nephrology and Hypertension Division Yogyakarta Indonesia -

Co-author 5

Danny Pratama Kuswadi danny.pratama.k@gmail.com Faculty of Medicine, Public Health and Nursing Gadjah Mada University Nephrology and Hypertension Division Yogyakarta Indonesia -

Co-author 6

Dwita Dyah Adyarini dwita.adyarini@mail.ugm.ac.id Faculty of Medicine, Public Health and Nursing Gadjah Mada University Nephrology and Hypertension Division Yogyakarta Indonesia -

Co-author 7

Siti Nur Rohmah siti.nur.r@ugm.ac.id Faculty of Medicine, Public Health and Nursing Gadjah Mada University Nephrology and Hypertension Division Yogyakarta Indonesia -

Co-author 8

Dyah Arum Kusuma Wardani dyaharumkw1988@gmail.com Faculty of Medicine, Public Health and Nursing Gadjah Mada University Fellow student of Nephrology and Hypertension Division Yogyakarta Indonesia *

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Kidney transplantation provides the best outcomes for patients with end-stage kidney disease. Many factors are influence the preoperative evaluation and selection of allograft donors, including the Human Leukocyte Antigens (HLA) which play a significant role. Recent studies shown that compatible Human Leukocyte Antigen (HLA) match has a positive effect on graft outcomes. However, the role of HLA matching in kidney allograft survival is still unclear. While HLA matching remains important for long-term outcomes, its impact on short term allograft function appears to be limited. This study examined the effect of HLA compatibility on short term kidney allograft survival, measured by serum creatinine and urine protein levels at three months after kidney transplantation.

Methods

A single centre retrospective cohort study was conducted on living donor kidney transplantation performed between January 2023 and June 2025 at tertiary referral hospital in Yogyakarta, Indonesia. Demographic and laboratory data were collected from medical records. The primary outcomes assessed were serum creatinine levels and urine protein levels at three months following kidney transplantation. Spearman’s correlation analysis was used to evaluate the relationship between HLA compatibility and and three-month renal allograft function.

Results

Thirty-six patients were included in the analysis. Recipients mean age 39.39±12.80 years, and most of the recipients were male (80.6%), HLA match were 38.72 ± 20.69. At three months, mean serum creatinine were decreased significantly from 6.70±4.31 mg/dL to 1.39±0.47 mg/dL and negative urine protein levels were increase from 39.1% to 64.5%. Overall, more HLA compatible were associated with decreased urine protein and creatinin serum levels at three months after kidney transplantations but not statistically significant (p>0.005).

Conclusion

HLA match did not significantly correlate with early allograft function as measured by creatinine, or urine protein levels at three months after kidney transplantation. These results indicate that many factors may influence the early post-transplant kidney function and more comprehensive study to determine the correlation between HLA match and allograft function. Further studies with larger sample sizes and longer follow-up period is recommended for better evaluation of factors that affect graft function.

Kewords